99841-68-6Relevant academic research and scientific papers
DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF
-
Paragraph 00179, (2013/03/26)
The present invention provides compounds of Formula (I) or a stereo isomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are agonists, partial agonists and modulators of the NPY Y4 rece
DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF
-
Paragraph 00199; 00229, (2013/03/26)
The present invention provides compounds of Formula (I), or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are agonists, partial agonists and modulators of the NPY Y4 rece
PURINE DERIVATIVES
-
Page/Page column 65, (2008/12/07)
Purine derivatives of Formula (I), wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as JAK3 kinase inhibitors.
PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS
-
Page/Page column 65-66, (2008/12/04)
Pyrrolopyrimidine derivatives of formula (I), wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as JAK3 kinase inhibitors.
Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
-
, (2008/06/13)
This invention provides pyridopyrimidines and 4-aminopyrimidines that are useful for treating cell proliferatives disorders, such as cancer and restenosis. We have now discovered a group of 7,8-dihydro-2 (amino and thio)pyrido[2,3-d]pyrimidines and 2,4-di
Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
-
, (2008/06/13)
This invention provides pyridopyrimidines and 4-aminopyrimidines that are useful for treating cell proliferative disorders, such as cancer and restenosis. We have now discovered a group of 7,8-dihydro-2-(amino and thio)pyrido[2,3-d]pyrimidines and 2,4-dia
SUBSTITUTED N-PHENYLPIPERIDINES AND DRUGS THEREFROM
-
, (2008/06/13)
Substituted N-phenylpiperidines I STR1 (R 1 =H, NO 2, CN, halogen, C 1-C 4-alkyl, CF 3, OCF 3, OH, CH 2 OH, COOH, CHO, NH--CHO, NH 2, CO--NH 2, 5-tetrazinyl, R 4--O--, R 4--O--CH 2--, R 4 O--CO--, R 4--CO--, R 4--NH--CO, R. sup.4--CO--NH--, R 4--SO 2--NH--; R. sup.2 =H, NO. sub.2, halogen, C 1-C 4-alkyl or R 4--O--; STR2 R 4 =C. sub.1-C 4-alkyl or phenyl which can carry one of the R 2 radicals;R 5, R 6 =H or one of the R 4 radicals; R 7 =one of the R 1 radicals;n=0 or 1; m=1 or 2; with the proviso that R 3 is STR3 only when n is 1, and the optical isomers in the case of optical isomerism, and the physiologically tolerated acid addition salts, are suitable as drugs.
